Latest Breaking News On - Clinical myeloma program at perlmutter cancer center - Page 1 : comparemela.com

Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets

United statesNew yorkSundar jagannathTisch cancer instituteClinical myeloma program at perlmutter cancer centerInternational staging systemMultiple myelomaMount sinaiAfrican americansBlood cancersClinical myeloma programPerlmutter cancer centerLinker mm1 studyBispecific antibodyAacr annual meeting